T. Momma

发表

Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.

M. Oya, N. Shigematsu, Shinya Sutani, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Plan reproducibility of intraoperatively custom-built linked seeds compared to loose seeds for prostate brachytherapy

N. Shigematsu, Shinya Sutani, T. Ohashi, 2018, Journal of contemporary brachytherapy.

Dosimetric effects of prone and supine positions on post-implant assessments for prostate brachytherapy

N. Shigematsu, T. Ohashi, Shoji Yamashita, 2013, Journal of contemporary brachytherapy.

The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study.

M. Jinzaki, K. Nakagawa, E. Kikuchi, 2014, Urologic oncology.

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

H. Nishimatsu, T. Tammela, A. Snapir, 2020, International Journal of Clinical Oncology.

Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.

K. Nakagawa, E. Kikuchi, A. Miyajima, 2015, The Journal of urology.

Metastatic Behavior of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: Association with Primary Tumor Location

M. Jinzaki, K. Nakagawa, E. Kikuchi, 2014, Annals of Surgical Oncology.

Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.

K. Nakagawa, M. Oya, M. Oyama, 2017, Urologic oncology.

Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.

K. Nakagawa, M. Oya, M. Oyama, 2016, Urologic oncology.

[The brachytherapy with low dose-rate iridium for prostate cancer].

T. Momma, K. Toya, S. Saito, 2000, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy.

K. Nakagawa, M. Oya, M. Oyama, 2019, Japanese journal of clinical oncology.

[A case of synchronous triple primary carcinomas of the kidney, bladder and prostate].

T. Momma, S. Saito, S. Hirose, 2003, Hinyokika kiyo. Acta urologica Japonica.

[Penile skin metastasis of gastric carcinoma associated with prostate carcinoma: a case report].

T. Momma, S. Kuramochi, S. Saito, 2001, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.

K. Nakagawa, E. Kikuchi, A. Miyajima, 2014, European urology.

Independent Predictors for Bladder Outcomes after Treatment of Intravesical Recurrence following Radical Nephroureterectomy in Patients with Primary Upper Tract Urothelial Carcinoma

M. Jinzaki, K. Nakagawa, E. Kikuchi, 2014, Annals of Surgical Oncology.

External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study.

K. Nakagawa, M. Oya, M. Oyama, 2016, European urology focus.

Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer.

T. Momma, A. Yorozu, S. Saito, 2022, Brachytherapy.

Pelvic congenital arteriovenous malformation diagnosed by transrectal ultrasonography: A case report.

T. Momma, Kenjiro Suzuki, N. Tanaka, 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy

M. Jinzaki, E. Kikuchi, M. Oya, 2014, Annals of Surgical Oncology.

Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy

E. Kikuchi, M. Oya, M. Oyama, 2017, Medical Oncology.

Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi‐institutions

K. Nakagawa, E. Kikuchi, A. Miyajima, 2013, BJU international.

Metanephric Adenoma Treated with Laparoscopic Nephrectomy

T. Momma, S. Kuramochi, R. Ohara, 2004, International journal of urology : official journal of the Japanese Urological Association.

Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score.

N. Shigematsu, Shinya Sutani, T. Ohashi, 2017, Brachytherapy.

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer

N. Shigematsu, T. Ohashi, Shoji Yamashita, 2014, Radiation Oncology.

Comparison of prostate verification with implanted gold markers in tissue surrounding the prostate and pelvic bony anatomy for external beam radiation therapy following low-dose-rate brachytherapy: a prospective clinical trial

N. Shigematsu, Shinya Sutani, T. Ohashi, 2020, Journal of radiation research.

Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.

K. Nakagawa, M. Oya, M. Oyama, 2016, Clinical genitourinary cancer.

Prostate‐specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low‐dose‐rate brachytherapy or external beam radiotherapy for localized prostate cancer

M. Oya, Tomoki Tanaka, N. Shigematsu, 2018, Cancer medicine.

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer

N. Shigematsu, T. Ohashi, Shoji Yamashita, 2014, Radiation oncology.

Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma

K. Nakagawa, M. Oya, M. Oyama, 2018, Japanese journal of clinical oncology.

Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy.

N. Shigematsu, T. Ohashi, T. Momma, 2007, Brachytherapy.

Serial changes of international prostate symptom score following I-125 prostate brachytherapy

T. Ohashi, T. Momma, A. Yorozu, 2006, International Journal of Clinical Oncology.

Impact of MRI-based postimplant dosimetric assessment in prostate brachytherapy using contrast-enhanced T1-weighted images.

Toshio Ohashi, Naoyuki Shigematsu, Takashi Hanada, 2010, Brachytherapy.

Acute urinary morbidity following I-125 prostate brachytherapy

T. Ohashi, T. Momma, A. Yorozu, 2005, International Journal of Clinical Oncology.

Brachytherapy for prostate cancer in Japan

M. Murai, T. Momma, S. Saito, 2001, International journal of urology : official journal of the Japanese Urological Association.

Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation.

N. Shigematsu, T. Ohashi, Shoji Yamashita, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Tri-modality Therapy with Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).

T. Fukagai, T. Momma, H. Konaka, 2023, International journal of radiation oncology, biology, physics.

Three‐year results of treatment for prostate cancer with low‐dose rate temporary iridium‐192 brachytherapy

M. Murai, T. Momma, A. Yorozu, 2006, International journal of urology : official journal of the Japanese Urological Association.

Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation.

N. Shigematsu, T. Ohashi, Shoji Yamashita, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.